Alavi Foumani Ali, Jafari Alireza, Tangestani Nejad Azita, Jafarinejhad Alireza, Ziyapour Shabnam, Keivanlou Mohammad Hossein, Afzalipour Masoumeh
Inflammatory Lung Disease Research Center, Department of Internal Medicine, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
Urology Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Tanaffos. 2023 Feb;22(2):221-229.
Bronchiectasis is a condition characterized by abnormal and permanent bronchial constriction that leads to sputum production and bronchial infection. The current study was done to evaluate the effects of symbiotic probiotics on the clinical manifestations and exacerbation of bronchiectasis.
26 patients in the placebo group (A) and 24 patients in the probiotic group (B) were allocated. In group A, patients took the placebo capsules two times daily for six months. In group B, patients took the LactoCare two times daily for six months.
The mean age of patients was 55.73±13.62 (group A) and 54.5±12.59 years (group B). Most of the patients had consumed azithromycin in both groups. The current study demonstrated there was no statistically significant difference between the decreased rate of pulmonary exacerbations in both groups. However, a decreasing trend was shown in the rate of pulmonary exacerbations without hospitalization (P=0.610). Also, there was a decreasing trend in the rate of pulmonary exacerbations leading to hospitalization (P=0.956). The most frequent etiologic pathogen was . FEV1 and FVC/FEV1 ratios were higher in group B than in group A. However, there was no statistically significant difference between groups A and B (P=0.908 vs 0.403).
The symbiotic probiotics were not effective in the clinical improvement of bronchiectasis, consumption of antibiotics, the rate of pulmonary exacerbations with or without hospitalization, FEV1 and FEV1/FVC, and microbiological pattern.
支气管扩张症是一种以异常且永久性支气管狭窄为特征的疾病，可导致痰液生成和支气管感染。本研究旨在评估共生益生菌对支气管扩张症临床表现及病情加重的影响。
将26例患者分配至安慰剂组（A组），24例患者分配至益生菌组（B组）。A组患者每日服用两次安慰剂胶囊，持续6个月。B组患者每日服用两次LactoCare，持续6个月。
患者的平均年龄在A组为55.73±13.62岁，在B组为54.5±12.59岁。两组中大多数患者都曾服用过阿奇霉素。本研究表明，两组肺部病情加重率的降低无统计学显著差异。然而，无需住院的肺部病情加重率呈下降趋势（P = 0.610）。导致住院的肺部病情加重率也呈下降趋势（P = 0.956）。最常见的病原体是 。B组的第一秒用力呼气容积（FEV1）和用力肺活量/第一秒用力呼气容积（FVC/FEV1）比值高于A组。然而，A组和B组之间无统计学显著差异（P = 0.908对0.403）。
共生益生菌在支气管扩张症的临床改善、抗生素使用、有无住院的肺部病情加重率、FEV1和FEV1/FVC以及微生物模式方面均无效。
